Neurocrine Biosciences
Neurocrine Biosciences Company Growth, Stability & Outlook
This page summarizes recurring themes identified from responses generated by popular LLMs to common candidate questions about Neurocrine Biosciences and has not been reviewed or approved by Neurocrine Biosciences.
What's the stability & growth outlook for Neurocrine Biosciences?
Strengths in market leadership, accelerating revenue, and a second growth pillar from a first‑in‑class launch are accompanied by pricing pressure, product concentration, and a moderated 2025 growth cadence. Together, these dynamics suggest a company with durable competitive advantages and solid growth that must navigate near‑term pricing, access, and mix headwinds to sustain resilience.
Key Insight for Candidates
Defining tradeoff: Heavy dependence on Ingrezza funds rapid expansion (Crenessity, late‑stage CNS) while pricing pressure and a fierce duopoly squeeze net price. Expect strong growth paired with heightened scrutiny, fast pivots, and outsized impact from access, guidance, and launch execution.Evidence in Action
- Guidance Discipline Cadence — 2025 Ingrezza guidance of $2.5–$2.55B and quarterly updates (e.g., Q3 2025 total net product sales $790M, +28% YoY) anchor a predictable operating rhythm. Teams plan against clear targets, adjust to mix/price shifts in real time, and sustain execution consistency despite payer pressure.
- First-in-Class Launch Sprints — Crenessity FDA approval on December 13, 2024 and a sales ramp of $14.5M (Q1), $53M (Q2), and $98M (Q3 2025) drive a launch-to-access sprint playbook. Field, market access, and medical teams synchronize around patient starts and coverage wins, building non‑Ingrezza revenue and speeding therapy adoption.
Positive Themes About Neurocrine Biosciences
-
Strong Market Position & Advantage: Reported results indicate category leadership in VMAT2 inhibitors by sales, with INGREZZA posting $2.3B in 2024 and guided to $2.5–$2.55B for 2025, outpacing Austedo’s outlook. Feedback suggests broader Medicare coverage and long‑term safety data help defend the TD/HD chorea franchise near term.
-
Diversified Revenue Streams: Reported FDA approval and early uptake of CRENESSITY create a new, defensible revenue stream in CAH alongside INGREZZA. Launch metrics referencing patient starts, payer coverage, and sequential sales growth through 2025 indicate increasing contribution.
-
Strong Revenue Growth: Reported financials show annual revenue grew about 25% in 2024 and total net product sales rose 28% year over year in Q3 2025. Momentum reflects sustained INGREZZA volume growth with incremental contribution from CRENESSITY.
Considerations About Neurocrine Biosciences
-
Weak Market Position & Pricing Challenges: Observed competition from Austedo and payer contracting introduces share and pricing pressure that can compress INGREZZA’s net price even as volumes rise. Management commentary highlights tighter insurance requirements and net‑price headwinds in 2025.
-
Undiversified Revenue Streams: Reported results show financials remain anchored by INGREZZA despite royalties and a new launch, leaving exposure to single‑product dynamics. Guidance sensitivity and access shifts can amplify variability.
-
Short-Term or Unsustainable Growth: Guidance and updates point to slower growth in 2025 versus 2024 as net‑price pressure and higher launch and R&D spend weigh on the pace. Feedback suggests near‑term margin headwinds and cadence moderation even as the top line expands.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
Neurocrine Biosciences Insights
Is This Your Company?
Claim Profile
